| Date | Title | Description | Source |
| 23.04.2024 | New report presents good figures from the Swiss biotech sect... |
The overall picture of the Swiss biotech industry in the Swiss Biotech Report published today is qu... | startuptic... |
| 05.04.2024 | Swiss healthcare innovators tap into the US market |
Basel-based startup Basilea Pharmaceutica announced the FDA approval of ZEVTERA, their antibacteria... | startuptic... |
| 02.04.2024 | A positive growth trajectory for three pharmaceutical startu... | Based in Basel, Santhera has pipeline of drugs for neuromuscular and pulmonary diseases that current... | startuptic... |
| 11.03.2024 | Continued strong Cresemba® (isavuconazole) sales performance... | - | globenewsw... |
| 19.01.2024 | Cresemba®-Verkaufszahlen in Lateinamerika lösen erste Umsatz... | Allschwil, 19. Januar 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches ... | einpresswi... |
| 19.01.2024 | Cresemba® sales in Latin America trigger first sales milesto... | Allschwil, Switzerland, January 19, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commerc... | einpresswi... |
| 15.01.2024 | Basilea announces acquisition of preclinical antibiotics pro... | Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad ran... | einpresswi... |
| 15.01.2024 | Basilea erwirbt präklinisches Antibiotika-Programm von Spexi... | Neuartige Antibiotika-Klasse Bakterizide Aktivität (in vitro und in vivo) gegenüber breitem Spektrum... | einpresswi... |
| 15.01.2024 | Basilea acquires Spexis preclinical antibiotics program | | startuptic... |
| 05.01.2024 | Basilea gibt Update zum Stand des Portfolios | Wesentliche Stärkung des klinischen Portfolios durch Business-Development-Aktivitäten im Jahr 2023; ... | einpresswi... |
| 05.01.2024 | Basilea provides portfolio status update | Clinical portfolio substantially strengthened through business development in 2023; two phase 3 stud... | einpresswi... |
| 13.11.2023 | Basilea erwirbt Fosmanogepix, ein Phase-3-bereites Breitspek... | Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 13. November 2023
Basilea Pharmaceutica AG, Allschwil... | einpresswi... |
| 13.11.2023 | Basilea announces acquisition of fosmanogepix, a phase-3-rea... | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, November 13, 2023
Basilea Pharmac... | einpresswi... |
| 15.08.2023 | Basilea meldet starkes Umsatz- und Gewinnwachstum im ersten ... | Anstieg der Einnahmen aus Cresemba® und Zevtera® auf CHF 80.5 Mio. (+57% im Vergleich zum Vorjahresz... | einpresswi... |
| 15.08.2023 | Basilea reports strong revenue and profit growth in first ha... | Increase in Cresemba® and Zevtera® related revenue to CHF 80.5 million (+57% year-on-year) Increase ... | einpresswi... |
| 23.03.2023 | Basilea announces CHF 5 million milestone payment from Asahi... | – Milestone related to the launch of Cresemba in Japan
Basel/Allschwil, Switzerland, March 23, 2023
... | einpresswi... |
| 23.03.2023 | Basilea announces CHF 5 million milestone payment from Asahi... | - | globenewsw... |
| 24.01.2023 | Basilea meldet für 2022 vorläufigen Betriebsgewinn, deutlich... | Erfolgreiche Umsetzung der strategischen Entscheidung, sich auf Antiinfektiva zu fokussieren und höh... | einpresswi... |
| 24.01.2023 | Basilea reports preliminary operating profit for 2022, signi... | Successful implementation of strategic decision to focus on anti-infectives and stronger than expect... | einpresswi... |
| 28.12.2022 | Basilea gibt Rückzahlung von 2022er Wandelanleihe bekannt | /EIN News/ -- Basel/Allschwil, 28. Dezember 2022
Basilea Pharmaceutica AG (SIX: BSLN), ein biopharma... | einpresswi... |
| 28.12.2022 | Basilea announces repayment of 2022 convertible bonds | /EIN News/ -- Basel/Allschwil, Switzerland, December 28, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN),... | einpresswi... |
| 23.12.2022 | Basilea announces regulatory approval of antifungal Cresemba... | Japanese regulatory authority granted marketing authorization to Basilea’s license partner, Asahi Ka... | einpresswi... |
| 23.12.2022 | Basilea gibt Zulassung für Antimykotikum Cresemba® (Isavucon... | Japanische Aufsichtsbehörde erteilt Marktzulassung an Basileas Lizenzpartner Asahi Kasei Pharma Zula... | einpresswi... |
| 19.12.2022 | Basilea announces transition milestone for oncology asset BA... | /EIN News/ -- Basel/Allschwil, Switzerland, December 19, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN)... | einpresswi... |
| 19.12.2022 | Basilea erreicht Transfer-Meilenstein für Onkologie-Wirkstof... | /EIN News/ -- Basel/Allschwil, 19. Dezember 2022
Basilea Pharmaceutica AG (SIX: BSLN), ein biopharma... | einpresswi... |
| 24.10.2022 | ERADICATE phase 3 study results highlight the potential role... | Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphyloc... | globenewsw... |
| 24.10.2022 | ERADICATE phase 3 study results highlight the potential role... | Late breaker presentation at IDWeek 2022 First double-blind registrational phase 3 study in Staphylo... | einpresswi... |
| 24.10.2022 | Ergebnisse der Phase-3-Studie ERADICATE unterstreichen die p... | Late-Breaking-Präsentation an der IDWeek 2022
Erste doppelt verblindete Phase-3-Zulassungsstudie in ... | einpresswi... |
| 13.10.2022 | Basilea announces late breaking presentation on the successf... | First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comp... | globenewsw... |
| 20.09.2022 | Basilea announces acquisition of rights for oncology asset B... | Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approxim... | globenewsw... |
| 13.09.2022 | Basilea sells preclinical oncology program for up to CHF242 ... | | startuptic... |
| 08.09.2022 | Basilea announces sale of preclinical oncology program to No... | Sale of Basilea’s novel PARG inhibitor discovery programUpfront and milestone payments of up to CHF ... | globenewsw... |
| 07.09.2022 | Basilea announces CHF 75 million senior secured loan agreeme... | Ad hoc announcement pursuant to Art. 53 LR
Basel/Allschwil, Switzerland, September 07, 2022
Basilea ... | globenewsw... |
| 16.08.2022 | Basilea reports strong financial half-year results and progr... | CHF 29 million royalty income (+22.5% year-on-year) reflecting continued commercial success of Crese... | globenewsw... |
| 12.07.2022 | Basilea announces Zevtera® (ceftobiprole) marketing authoriz... | Basel/Allschwil, Switzerland, July 12, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stag... | globenewsw... |
| 28.06.2022 | Basilea announces positive results of phase 3 ERADICATE stud... | Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Applica... | globenewsw... |
| 27.06.2022 | Basilea reports progress on the implementation of its strate... | ERADICATE phase 3 study exploring ceftobiprole for the treatment of patients with Staphylococcus aur... | globenewsw... |
| 24.06.2022 | Basilea announces approval for additional formulation of ant... | Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s l... | globenewsw... |
| 17.06.2022 | Cresemba® sales in Asia Pacific region trigger sales milesto... | Basel/Allschwil, Switzerland, June 17, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stag... | globenewsw... |
| 27.04.2022 | Basilea announces licensing of a novel first-in-class antifu... | Basel, Switzerland, April 27, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopha... | globenewsw... |
| 13.04.2022 | Basilea shareholders approve all proposals of the board of d... | Press Release
Basel, Switzerland, April 13, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported tod... | globenewsw... |
| 13.04.2022 | Basilea reports preclinical data on oncology drug candidates... | Basel, Switzerland, April 13, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopha... | globenewsw... |
| 08.03.2022 | Basilea reports preclinical data on anti-cancer activity of ... | Press Release
Basel, Switzerland, March 08, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercia... | globenewsw... |
| 15.02.2022 | Basilea to become a leading anti-infectives company backed b... | 65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.... | globenewsw... |
| 24.01.2022 | Basilea reports updated interim results for iCCA patients wi... | Basel, Switzerland, January 24, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biop... | globenewsw... |
| 24.01.2022 | Basilea Pharmaceutica : Updated January 24, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presen... | marketscre... |
| 13.01.2022 | Basilea announces approval of antifungal Cresemba® (isavucon... | Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s l... | globenewsw... |
| 11.01.2022 | Basilea announces completion of patient enrolment in phase 3... | Basel, January 11, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical... | globenewsw... |
| 11.01.2022 | Basilea Pharmaceutica : Updated January 11, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presen... | marketscre... |
| 10.01.2022 | Basilea Pharmaceutica : Updated January 10, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presen... | marketscre... |
| 10.01.2022 | Basilea exceeds 2021 financial guidance on preliminary reven... | Total revenue of CHF 148 million exceeding 2021 financial guidance, driven by 65% increase in non-de... | globenewsw... |
| 07.01.2022 | Strong Cresemba® (isavuconazole) sales by Astellas in the U.... | Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, January 07, 2022
Basilea Pharmaceutic... | globenewsw... |
| 07.01.2022 | Basilea Pharmaceutica : Updated January 07, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presen... | marketscre... |
| 06.01.2022 | Basilea Pharmaceutica : Updated January 06, 2022 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presen... | marketscre... |
| 06.01.2022 | Basilea reports on portfolio progress made in 2021 | Achieved important Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) milestones Added new clinic... | globenewsw... |
| 22.12.2021 | Basilea receives USD 10 million milestone payment related to... | Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to me... | marketscre... |
| 21.12.2021 | Basilea receives USD 10 million milestone payment related to... | Chinese National Medical Products Administration (NMPA) granted Drug Approval License for Cresemba i... | globenewsw... |
| 21.12.2021 | Basilea receives USD 10 million milestone payment related to... | (MORE TO FOLLOW) Dow Jones Newswires
December 21, 2021 01:15 ET (06:15 GMT) | marketscre... |
| 21.12.2021 | Basilea receives USD 10 million milestone payment related to... | Chinese National Medical Products Administration (NMPA) granted Drug Approval License for Cresemba i... | marketscre... |
| 17.12.2021 | Basilea Pharmaceutica : Updated December 17, 2021 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presen... | marketscre... |
| 17.12.2021 | Basilea announces FDA approval of Investigational New Drug a... | Phase 1 study in patients with advanced solid tumors planned to start in the first quarter of 2022
A... | globenewsw... |
| 08.12.2021 | Continued strong Cresemba® (isavuconazole) sales by Pfizer t... | Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, December 08, 2021
Basilea Pharmaceuti... | globenewsw... |
| 16.11.2021 | Basilea Pharmaceutica : Updated November 16, 2021 | Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presen... | marketscre... |
| 16.11.2021 | Basilea announces submission of Investigational New Drug app... | Potential to add third clinical-stage program to oncology pipelineProgressing patient enrolment towa... | globenewsw... |
| 11.10.2021 | Basilea presents preclinical data on synergy between derazan... | Basel, Switzerland, October 11, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the pres... | globenewsw... |
| 01.04.2021 | Basilea announces closing of previously announced transactio... | Basel, Switzerland, April 01, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced the succes... | marketscre... |
| 24.02.2021 | Basilea platziert erfolgreich 1 Million neue Namenaktien und... | NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN O... | globenewsw... |
| 24.02.2021 | Basilea successfully placed 1 million new registered shares,... | NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN O... | globenewsw... |
| 23.02.2021 | Basilea launches a private placement of new shares by way of... | NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN O... | globenewsw... |
| 16.02.2021 | Basilea meldet für 2020 starke Finanzergebnisse und deutlich... | Zweistelliges Wachstum der direkt realisierten Umsatzbeiträge durch Cresemba und Zevtera
Betriebsver... | globenewsw... |
| 16.02.2021 | Basilea reports strong 2020 financial results and significan... | Double-digit growth in Cresemba and Zevtera non-deferred revenue contributions
Operating loss reduce... | globenewsw... |
| 15.02.2021 | Basilea announces divestment of its Chinese R&D subsidia... | Basel, Switzerland, February 15, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it... | globenewsw... |
| 12.02.2021 | Basilea reports derazantinib/PD-L1 checkpoint inhibitor comb... | Basel, Switzerland, February 12, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that da... | globenewsw... |
| 11.02.2021 | Basilea achieves preclinical milestone in oncology collabora... | Basel, Switzerland, February 11, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it... | globenewsw... |
| 11.02.2021 | Basilea erreicht präklinischen Meilenstein im Rahmen einer K... | Basel, 11. Februar 2021
Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie einen niede... | globenewsw... |
